Crispr Therapeutics Coverage Assumed by Guggenheim at Neutral
Guggenheim Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating
Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued."
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
Intellia Therapeutics Presents Data On Redosing With In Vivo CRISPR Therapy; 55 Mg NTLA-2001 Dose Shows 90% Median Reduction In Serum TTR At Day 28; Well Tolerated Across All Patients; Potential Redosing Advantage For Future Therapies
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
CRISPR Therapeutics Stock (NASDAQ:CRSP): Will It Take Off Anytime Soon?
Top Gap Ups and Downs on Monday: AVGO, DELL, SONY and More
Crispr Therapeutics Price Target Maintained With a $105.00/Share by Piper Sandler
Express News | Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Maintains $105 Price Target
Needham Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $88
Piper Sandler Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $105
Express News | Needham Reiterates Buy on CRISPR Therapeutics, Maintains $88 Price Target
CRISPR Therapeutics Analyst Ratings
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
S&P 500 Futures Up In Premarket Trading; Broadcom, Tesla Lead
CRISPR Therapeutics (CRSP) Presents at Goldman Sachs 45th Annual Global Healthcare Conference - Company Call Transcript
CRISPR Therapeutics AG (CRSP) Is Attracting Investor Attention: Here Is What You Should Know
Why Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report?